T

he world is going to have to wait a little longer for the Merck Ebola vaccine.

Though Merck had repeatedly said it would file its licensure application with the Food and Drug Administration by the end of 2017, the company will not meet that self-imposed target, the team leader for the Ebola vaccine project told STAT on Friday.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.